State Street discloses 5.1% Celldex (CLDX) ownership stake filing
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
State Street Corporation filed a Schedule 13G reporting a passive ownership stake in Celldex Therapeutics, Inc. common stock. As of 12/31/2025, State Street reported beneficial ownership of 3,397,713 shares, representing 5.1% of Celldex’s outstanding common stock.
State Street reported shared voting power over 3,194,178 shares and shared dispositive power over 3,397,713 shares, with no sole voting or dispositive authority. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of Celldex.
Positive
- None.
Negative
- None.
FAQ
What ownership stake did State Street report in Celldex (CLDX)?
State Street reported beneficial ownership of 3,397,713 Celldex common shares, representing 5.1% of the class as of 12/31/2025. This crosses the 5% threshold that requires a Schedule 13G disclosure with the SEC.
Is State Street’s Celldex (CLDX) stake considered passive or activist?
The Schedule 13G certification states the Celldex securities were acquired and are held in the ordinary course of business and not for changing or influencing control. This language characterizes State Street’s position as a passive institutional holding.
Which State Street affiliates are associated with the Celldex (CLDX) holdings?
The filing lists several investment adviser subsidiaries, including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, and State Street Global Advisors Trust Company as entities connected to the reported beneficial ownership.
Why did State Street have to file a Schedule 13G for Celldex (CLDX)?
Schedule 13G is required when an investor exceeds 5% beneficial ownership of a registered class of equity securities. State Street reported owning 5.1% of Celldex common stock as of 12/31/2025, triggering this beneficial ownership disclosure requirement.